← All indications
Frontotemporal Dementia
The most common clinical form of FRONTOTEMPORAL LOBAR DEGENERATION, this dementia presents with personality and behavioral changes often associated with disinhibition, apathy, and lack of insight.
Subtype terms (1)
More specific conditions that are subtypes of Frontotemporal Dementia in the MeSH hierarchy.
- Pick Disease of the Brain
3 drugs approved
Drugs by status
Approved for this indication (1)
Phase 4 trials (6)
Phase 3 trials (1)
Phase 2 trials (13)
Phase 1 trials (5)
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (25)
- Avid Radiopharmaceuticals
- Cyclotherapeutics
- FORUM Pharmaceuticals Inc
- National Institutes of Health (NIH)
- National Human Genome Research Institute (NHGRI)
- National Institute of Neurological Disorders and Stroke (NINDS)
- Chang Gung University
- Cornell University
- HealthPartners Institute
- University of Florida
- Columbia University
- University of Minnesota
- Salford Royal Foundation NHS Trust
- University of Oxford
- CHU Purpan
- University of Nantes
- University of Paris
- Washington University in St. Louis
- University of Western Ontario
- Canadian Institutes of Health Research (CIHR)
- Berry Consultants
- University of Rennes
- The Weston A. Price Foundation
- IntraBio Inc
- Prevail Therapeutics
Organization Involved with Phase 1 Indications (12)
Organization Involved with Other Experimental Indications (3)